Article Details

Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial

Retrieved on: 2022-08-03 12:02:44

Tags for this article:

Click the tags to see associated articles and topics

Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial. View article details on HISWAI: https://www.globenewswire.com/news-release/2022/08/03/2491350/0/en/Landos-Biopharma-Reports-Positive-Top-Line-Results-From-NX-13-Phase-1b-Trial.html

Excerpt

NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up